Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
This real-world analysis investigated patients with follicular lymphoma in Italy receivingthree or more treatment lines (3L), focusing on therapeutic pathways with their rebounds onhealthcare resource consumptions and costs. Data were retrieved from administrative databases fromhealthcare entities covering about 13.3 million residents. Adults diagnosed with follicular lymphomawere identified between January 2015 and June 2020, and among… Leggi tutto »Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Background: This real-world analysis evaluated drug utilization focusing on wastage and healthcare costsfor treatment of patients with advanced breast cancer (aBC) hormone receptor-positive (HR+)/humanepidermal growth factor receptor-2 negative (HER2-) in Italy.Methods: A retrospective analysis was conducted on administrative data covering about 13.3 millionhealth-assisted individuals. Across January/2017–June/2021, all patients with HR+/HER2-aBC wereidentified by ≥ 1 prescription… Leggi tutto »Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy
Real-world Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy
In recent years, an increasing trend in the incidence of melanoma has been observed in Europe. Although early diagnosis and prompt intervention with local resection often results in positive outcomes, conversely, metastatic disease is still clinically challenging with a poor prognosis and a 5-year survival of around 30%. The growing awareness of melanoma biology and… Leggi tutto »Real-world Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy
Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to… Leggi tutto »Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing… Leggi tutto »The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy